Cholinesterase inhibitors in Alzheimer's disease: A consensus view on managing treatment failure

Murat Emre, Martin Farlow, Roger Bullock, Serge Gauthier, George Grossberg, Steven G. Potkin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Initial treatment of Alzheimer's disease (AD) with a cholinesterase (ChE) inhibitor may fail to provide benefits due to lack/loss of efficacy or poor tolerability. Since the available ChE inhibitors differ in their pharmacological profiles, switching is an option which should be considered when initial treatment is unsuccessful. Preliminary evidence from open studies and case series suggest that patients who fail to draw benefit from an initial drug may still improve when a second ChE inhibitor is administered. Switching should only be considered when a patient does not respond to the first drug, when initial efficacy is lost or when the drug is poorly tolerated. A proper trial of the first agent should be given, with appropriate doses for a sufficient length of time before concluding a therapeutic failure. Switching can be undertaken without a wash out period if the issue is lack/loss of efficacy, but a wash out period of 1-2 weeks should be allowed if a patient is switched for poor tolerability.

Original languageEnglish
Pages (from-to)29-30
Number of pages2
JournalPrimary Care Psychiatry
Volume9
Issue number1
DOIs
StatePublished - 2003

Fingerprint

Cholinesterase Inhibitors
Treatment Failure
Consensus
Alzheimer Disease
Pharmaceutical Preparations
Therapeutics
Pharmacology

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitors

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Cholinesterase inhibitors in Alzheimer's disease : A consensus view on managing treatment failure. / Emre, Murat; Farlow, Martin; Bullock, Roger; Gauthier, Serge; Grossberg, George; Potkin, Steven G.

In: Primary Care Psychiatry, Vol. 9, No. 1, 2003, p. 29-30.

Research output: Contribution to journalArticle

Emre, Murat ; Farlow, Martin ; Bullock, Roger ; Gauthier, Serge ; Grossberg, George ; Potkin, Steven G. / Cholinesterase inhibitors in Alzheimer's disease : A consensus view on managing treatment failure. In: Primary Care Psychiatry. 2003 ; Vol. 9, No. 1. pp. 29-30.
@article{30f1650c21014b35a19ff1bba56a6fab,
title = "Cholinesterase inhibitors in Alzheimer's disease: A consensus view on managing treatment failure",
abstract = "Initial treatment of Alzheimer's disease (AD) with a cholinesterase (ChE) inhibitor may fail to provide benefits due to lack/loss of efficacy or poor tolerability. Since the available ChE inhibitors differ in their pharmacological profiles, switching is an option which should be considered when initial treatment is unsuccessful. Preliminary evidence from open studies and case series suggest that patients who fail to draw benefit from an initial drug may still improve when a second ChE inhibitor is administered. Switching should only be considered when a patient does not respond to the first drug, when initial efficacy is lost or when the drug is poorly tolerated. A proper trial of the first agent should be given, with appropriate doses for a sufficient length of time before concluding a therapeutic failure. Switching can be undertaken without a wash out period if the issue is lack/loss of efficacy, but a wash out period of 1-2 weeks should be allowed if a patient is switched for poor tolerability.",
keywords = "Alzheimer's disease, Cholinesterase inhibitors",
author = "Murat Emre and Martin Farlow and Roger Bullock and Serge Gauthier and George Grossberg and Potkin, {Steven G.}",
year = "2003",
doi = "10.1185/135525703125002739",
language = "English",
volume = "9",
pages = "29--30",
journal = "Primary Care Psychiatry",
issn = "1355-2570",
publisher = "Librapharm",
number = "1",

}

TY - JOUR

T1 - Cholinesterase inhibitors in Alzheimer's disease

T2 - A consensus view on managing treatment failure

AU - Emre, Murat

AU - Farlow, Martin

AU - Bullock, Roger

AU - Gauthier, Serge

AU - Grossberg, George

AU - Potkin, Steven G.

PY - 2003

Y1 - 2003

N2 - Initial treatment of Alzheimer's disease (AD) with a cholinesterase (ChE) inhibitor may fail to provide benefits due to lack/loss of efficacy or poor tolerability. Since the available ChE inhibitors differ in their pharmacological profiles, switching is an option which should be considered when initial treatment is unsuccessful. Preliminary evidence from open studies and case series suggest that patients who fail to draw benefit from an initial drug may still improve when a second ChE inhibitor is administered. Switching should only be considered when a patient does not respond to the first drug, when initial efficacy is lost or when the drug is poorly tolerated. A proper trial of the first agent should be given, with appropriate doses for a sufficient length of time before concluding a therapeutic failure. Switching can be undertaken without a wash out period if the issue is lack/loss of efficacy, but a wash out period of 1-2 weeks should be allowed if a patient is switched for poor tolerability.

AB - Initial treatment of Alzheimer's disease (AD) with a cholinesterase (ChE) inhibitor may fail to provide benefits due to lack/loss of efficacy or poor tolerability. Since the available ChE inhibitors differ in their pharmacological profiles, switching is an option which should be considered when initial treatment is unsuccessful. Preliminary evidence from open studies and case series suggest that patients who fail to draw benefit from an initial drug may still improve when a second ChE inhibitor is administered. Switching should only be considered when a patient does not respond to the first drug, when initial efficacy is lost or when the drug is poorly tolerated. A proper trial of the first agent should be given, with appropriate doses for a sufficient length of time before concluding a therapeutic failure. Switching can be undertaken without a wash out period if the issue is lack/loss of efficacy, but a wash out period of 1-2 weeks should be allowed if a patient is switched for poor tolerability.

KW - Alzheimer's disease

KW - Cholinesterase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0345119877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345119877&partnerID=8YFLogxK

U2 - 10.1185/135525703125002739

DO - 10.1185/135525703125002739

M3 - Article

AN - SCOPUS:0345119877

VL - 9

SP - 29

EP - 30

JO - Primary Care Psychiatry

JF - Primary Care Psychiatry

SN - 1355-2570

IS - 1

ER -